Neutralizing antibody testing service
Innatoss has broadened its mission “Catch it early! And significantly reduce healthcare issues associated with infectious diseases” to COVID-19 in the face of the 2020 epidemic.
From April to August 2020, Innatoss has offered testing service for SARS-CoV-2 antibodies to individuals who had experienced symptoms consistent with COVID-19, but had no access to RT-PCR testing in the early phase of the pandemic. We employed a highly specific two-tiered testing strategy using a rapid test followed by an ELISA for confirmation of positive results. Both tests were certified for diagnostic use and verified by Innatoss.
Starting from September 2020 onwards, Innatoss is the first medical lab in Europe that offers testing for neutralizing antibodies against SARS-CoV-2 for the public. Innatoss recently performed a study in Kessel, a city in the south of the Netherlands that was severely affected during the first wave of COVID-19, to determine the longevity of binding antibodies versus neutralizing antibodies in individuals. Individuals were followed up to 5 months after their initial infection. Over a time-frame of 2-3 months, in 90 percent of the cases the levels of binding antibody dropped significantly while the level of functional antibodies (neutralizing antibodies) was stable in 70 percent of those tested.